887 related articles for article (PubMed ID: 26486789)
1. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
Fischer K; Bahlo J; Fink AM; Goede V; Herling CD; Cramer P; Langerbeins P; von Tresckow J; Engelke A; Maurer C; Kovacs G; Herling M; Tausch E; Kreuzer KA; Eichhorst B; Böttcher S; Seymour JF; Ghia P; Marlton P; Kneba M; Wendtner CM; Döhner H; Stilgenbauer S; Hallek M
Blood; 2016 Jan; 127(2):208-15. PubMed ID: 26486789
[TBL] [Abstract][Full Text] [Related]
2. Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
Herling CD; Coombes KR; Benner A; Bloehdorn J; Barron LL; Abrams ZB; Majewski T; Bondaruk JE; Bahlo J; Fischer K; Hallek M; Stilgenbauer S; Czerniak BA; Oakes CC; Ferrajoli A; Keating MJ; Abruzzo LV
Lancet Oncol; 2019 Nov; 20(11):1576-1586. PubMed ID: 31582354
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
Davids MS; Brander DM; Kim HT; Tyekucheva S; Bsat J; Savell A; Hellman JM; Bazemore J; Francoeur K; Alencar A; Shune L; Omaira M; Jacobson CA; Armand P; Ng S; Crombie J; LaCasce AS; Arnason J; Hochberg EP; Takvorian RW; Abramson JS; Fisher DC; Brown JR;
Lancet Haematol; 2019 Aug; 6(8):e419-e428. PubMed ID: 31208944
[TBL] [Abstract][Full Text] [Related]
4. Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
Herishanu Y; Tadmor T; Braester A; Bairey O; Aviv A; Rahimi-Levene N; Fineman R; Levi I; Yuklea M; Ruchlemer R; Shvidel L; Polliack A
Hematol Oncol; 2019 Apr; 37(2):185-192. PubMed ID: 30756414
[TBL] [Abstract][Full Text] [Related]
5. Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group.
Smolej L; Brychtová Y; Cmunt E; Doubek M; Špaček M; Belada D; Šimkovič M; Stejskal L; Zygulová I; Urbanová R; Brejcha M; Zuchnická J; Móciková H; Kozák T;
Br J Haematol; 2021 May; 193(4):769-778. PubMed ID: 33618437
[TBL] [Abstract][Full Text] [Related]
6. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
Shanafelt TD; Wang XV; Kay NE; Hanson CA; O'Brien S; Barrientos J; Jelinek DF; Braggio E; Leis JF; Zhang CC; Coutre SE; Barr PM; Cashen AF; Mato AR; Singh AK; Mullane MP; Little RF; Erba H; Stone RM; Litzow M; Tallman M
N Engl J Med; 2019 Aug; 381(5):432-443. PubMed ID: 31365801
[TBL] [Abstract][Full Text] [Related]
8. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
[TBL] [Abstract][Full Text] [Related]
9. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
Thompson PA; Tam CS; O'Brien SM; Wierda WG; Stingo F; Plunkett W; Smith SC; Kantarjian HM; Freireich EJ; Keating MJ
Blood; 2016 Jan; 127(3):303-9. PubMed ID: 26492934
[TBL] [Abstract][Full Text] [Related]
11. FCR achieves long-term durable remissions in patients with
Chai-Adisaksopha C; Brown JR
Blood; 2017 Nov; 130(21):2278-2282. PubMed ID: 29025740
[TBL] [Abstract][Full Text] [Related]
12. Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
Munir T; Howard DR; McParland L; Pocock C; Rawstron AC; Hockaday A; Varghese A; Hamblin M; Bloor A; Pettitt A; Fegan C; Blundell J; Gribben JG; Phillips D; Hillmen P
Leukemia; 2017 Oct; 31(10):2085-2093. PubMed ID: 28216660
[TBL] [Abstract][Full Text] [Related]
13. Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group.
Cramer P; Fink AM; Busch R; Eichhorst B; Wendtner CM; Pflug N; Langerbeins P; Bahlo J; Goede V; Schubert F; Döhner H; Stilgenbauer S; Dreger P; Kneba M; Böttcher S; Mayer J; Hallek M; Fischer K
Leuk Lymphoma; 2013 Aug; 54(8):1821-2. PubMed ID: 23631654
[TBL] [Abstract][Full Text] [Related]
14. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.
Gozzetti A; Candi V; Fabbri A; Schiattone L; Cencini E; Lauria F; Frasconi A; Crupi R; Raspadori D; Papini G; Defina M; Bartalucci G; Bocchia M
Leuk Res; 2014 Aug; 38(8):891-5. PubMed ID: 24934847
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
Short NJ; Keating MJ; Wierda WG; Faderl S; Ferrajoli A; Estrov Z; Smith SC; O'Brien SM
Cancer; 2015 Nov; 121(21):3869-76. PubMed ID: 26218678
[TBL] [Abstract][Full Text] [Related]
16. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ;
Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274
[TBL] [Abstract][Full Text] [Related]
17. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.
Strati P; Wierda W; Burger J; Ferrajoli A; Tam C; Lerner S; Keating MJ; O'Brien S
Cancer; 2013 Nov; 119(21):3805-11. PubMed ID: 23943357
[TBL] [Abstract][Full Text] [Related]
18. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
19. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial.
Herling CD; Cymbalista F; Groß-Ophoff-Müller C; Bahlo J; Robrecht S; Langerbeins P; Fink AM; Al-Sawaf O; Busch R; Porcher R; Cazin B; Dreyfus B; Ibach S; Leprêtre S; Fischer K; Kaiser F; Eichhorst B; Wentner CM; Hoechstetter MA; Döhner H; Leblond V; Kneba M; Letestu R; Böttcher S; Stilgenbauer S; Hallek M; Levy V
Leukemia; 2020 Aug; 34(8):2038-2050. PubMed ID: 32071431
[TBL] [Abstract][Full Text] [Related]
20. A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia.
Izutsu K; Kinoshita T; Takizawa J; Fukuhara S; Yamamoto G; Ohashi Y; Suzumiya J; Tobinai K
Jpn J Clin Oncol; 2021 Mar; 51(3):408-415. PubMed ID: 33244584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
